CNS, BDC to join forces for biotech consulting
Clinical Network Services (CNS) has entered a partnership with Biologics Development Consultancy (BDC) and has hired a new principal consultant for its London team.
CNS and BDC have agreed to a collaborative partnership aimed at allowing each company to expand the expertise they can offer their clients.
Brisbane-headquartered CNS provides services for the planning, implementation and delivery of preclinical, phase I and phase II trials. The company operates BioDesk, a product development and regulatory planning consultancy for biotech companies.
BDC is a regulatory and product development consulting firm based in the Netherlands, focused on assisting in the development of biotech, biologic and drug products.
“The partnership with BDC is a very strong signal to our market that CNS continues to build a world-class regulatory and preclinical consulting service,” BioDesk director Mark Reid said.
CNS also revealed it has appointed Dr Richard Turner as principal consultant for the company’s London team. Turner is a former pharmaceutical and scientific assessor at what is now the UK MHRA, and was most recently director of regulatory affairs at Daiichi Sankyo.
CNS opened its London office in March, expanding beyond its core markets of Australia and New Zealand.
The company has now been granted SME status by the European Medicines Agency, entitling it to financial and administrative support from the regulatory body.
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
